(Alliance News) - Destiny Pharma PLC said Tuesday new guidelines issued by the Asia Pacific Society for Infection Control "underline the market potential" of its lead product, XF-73.
The guidelines - for prevention of surgical site infections - recommend decolonisation of staphylococcus aureus in surgical patients to prevent infections.
Destiny Pharma said XF-73 is in Phase 2b clinical trials, where it is being tested on its ability to kill staphylococcus aureus bacteria in the patient's nose prior to surgery. This, the company said, will reduce the potential for serious post-surgical bacterial infections.
Chief Executive Neil Clark said: "This new Asian review strongly supports the potential for Destiny Pharma's lead product, XF-73, to meet the guidelines' clinical recommendation to prevent post-surgical infections by decolonising whilst mitigating the emergence of antimicrobial resistance.
"Previous independent publications in the US and from the World Health Organisation already support this approach. XF-73 nasal gel is currently in a Phase 2b clinical trial in the US and Europe and we look forward to reporting results in mid-2020. There is a significant commercial opportunity for XF-73, which is estimated to have potential peak annual product sales of USD1 billion in the US alone."
Shares in Destiny Pharma were 1.8% higher in London at 42.24 pence each.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)